Open access
Aug 2026
Functional and biochemical characterization of Alyftrek® components reveals high-potency rescue of F508del-CFTR.
Alyftrek® (vanzacaftor/tezacaftor/deutivacaftor, VTD) is a triple CFTR modulator therapy for patients with cystic fibrosis (CF). In this study, we characterized the pharmacological properties of vanzacaftor and deutivacaftor using functional and biochemical assays in patients derived primary bronchial epithelial (HBE)...
S. Mirval, Louise Damy, Auguste Sauvage de Gérando et al.
· American Journal of Physiolo... · 0 citations